Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 412 across all filing types
Latest filing 2025-01-08 Earnings Release
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Erfolgreiche Unternehmensentwicklung und vielversprechende Fortschritte bei Beteiligungen im Jahr 2024
Earnings Release Classification · 100% confidence The document is a news release dated January 8, 2025, from NanoRepro AG, announcing preliminary figures and operational highlights for the fiscal year 2024. It details revenue development, growth in core business segments (self-tests and supplements), and updates on strategic investments (PaediProtect and Deutsche Kosmetikwerke AG). This content structure—providing key financial metrics and business updates immediately following the period end, often via a news wire service (EQS-News)—is characteristic of an Earnings Release (ER) or a preliminary results announcement, rather than the full, comprehensive Annual Report (10-K) or a formal Interim Report (IR). Since it explicitly states it is announcing 'vorläufige Zahlen' (preliminary figures) and focuses on key highlights and strategic progress for the past year, the most appropriate classification is Earnings Release (ER). It is not a transcript (CT), a proxy statement (PSI), or a formal regulatory filing like a 10-K. FY 2024
2025-01-08 German
NanoRepro AG: Dr. Olaf Stiller, Kauf
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains structured information detailing a transaction ('Kauf' - Purchase) by a member of the supervisory board ('Aufsichtsrat'), Dr. Olaf Stiller, in the company's shares (NanoRepro AG). This directly corresponds to the definition of Director's Dealing reports, which track personal share transactions by executives and directors.
2024-10-29 German
Halbjahresabschluss 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresabschluss' (Half-Year Financial Report) for NanoRepro AG as of 30.06.2024. It contains a management report (Lagebericht) and financial statements (Jahresabschluss including balance sheet and P&L). This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2024
2024-10-23 German
NanoRepro AG: Dr. Olaf Stiller, Kauf
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction ('Kauf' - Purchase) made by a member of the supervisory board ('Aufsichtsrat'), Dr. Olaf Stiller, in the company's shares (NanoRepro AG). The structure follows standard regulatory disclosure formats for insider transactions, specifically mentioning 'Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen' (Notification and public disclosure of transactions by persons discharging managerial responsibilities). This directly corresponds to the definition of Director's Dealing.
2024-10-22 German
NanoRepro AG: NanoRepro veroffentlicht Halbjahreszahlen 2024 Umsatz im Kerngeschaft steigt, Investitionen in Markenbekanntheit zahlen sich aus
Earnings Release Classification · 100% confidence The document is a press release dated October 16, 2024, titled "NanoRepro veröffentlicht Halbjahreszahlen 2024" (NanoRepro publishes half-year figures 2024). It explicitly discusses financial results for the first half of 2024 (H1 2024), including revenue, EBIT, net income, and balance sheet figures as of June 30, 2024. This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it is presented as a news release (EQS-News), the core content is the comprehensive summary of the half-year financial performance, making 'IR' the most accurate classification over a simple 'ER' (Earnings Release, which is usually just highlights) or 'RPA' (Report Publication Announcement, which usually just announces the report is available). The document contains key figures and management commentary typical of a formal interim report. H1 2024
2024-10-16 German
NanoRepro AG: NanoRepro AG erwirbt Mehrheitsbeteiligung von 50,03 Prozent an der Paedi Protect AG
Board/Management Information Classification · 95% confidence The document is a news release dated October 15, 2024, announcing that NanoRepro AG acquired a majority stake (50.03%) in Paedi Protect AG. It details the strategic rationale, the transaction price, and subsequent management changes at the acquired company. The format (EQS-News, date, headline structure) strongly suggests a corporate announcement. Since it is not a full annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a proxy statement (DEF 14A/PSI), and it specifically concerns a change in corporate structure/ownership via acquisition, it falls under the category of Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category fits perfectly. However, the core subject is a significant investment/acquisition, which aligns best with 'Capital/Financing Update' (CAP) as it involves capital structure change and fundraising context, although 'M&A Activity' (TAR) is also relevant for acquisitions. Given the focus on increasing shareholding and financing the acquisition ('Finanzierung des Erwerbs aus eigenen Mitteln'), CAP is a strong fit, but TAR (Merger/Takeover Activity) is often used for acquisitions. Since this is an acquisition of a majority stake, TAR is the most precise fit for M&A activity. If TAR is reserved strictly for public takeover bids, CAP is the next best fit for financing/capital structure changes resulting from the deal. Reviewing the definitions, TAR is for 'merger proposals or takeover bids'. This is an acquisition of a majority stake in a non-listed company, which is a form of M&A. I will classify it as TAR.
2024-10-15 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.